ACT-AD Activities

ACT-AD and our members conduct activities throughout the year to focus attention on the need to accelerate cures and treatments for Alzheimer’s disease.

May 14, 2008
ACT-AD chairman Daniel Perry participated in a panel presentation at Dialogue on Diversity's 2008 Health Care Symposium.
View Slides

March 31, 2008
ACT-AD Members Urge House and Senate Appropriations Subcommittee Chairs to Increase Funds for FDA Drug Review Activities in FY 2009.
Read Letter

March 13, 2008
ACT-AD, together with the Alzheimer’s Association and the Alzheimer’s Study Group, hosts a scientific workshop to stimulate an open discussion with FDA leadership on the subject of clinical meaningfulness in new AD therapies and help advance the dialogue regarding how best to measure the clinical effectiveness of emerging therapies.
See Press Release : Read Alzheimer Research Forum Article

November 13, 2007
Alzheimer's Foundation's J. Weeson Op-Ed on Alzheimer's screening is published in the Sacramento Bee
Read Op-Ed

November 2, 2007
Congressman Tom Latham's holds a roundtable discussion on aging and Alzheimer’s disease with Dr. Molly Wagster, Ph.D.,  Dan Perry and Stephen McConnell. Wagster is Chief of the Behavioral and Systems Neuroscience Branch of the Neuroscience and Neuropsychology of Aging Program at the National Institute on Aging (NIA), a branch of the National Institutes of Health (NIH). Perry is the Executive Director of the not-for-profit Alliance for Aging Research. McConnell is the Vice President for Advocacy and Public Policy at the Alzheimer’s Association.
Watch and listen to the discussion

October 17, 2007
FDA convenes a meeting of neurological disease advocacy and research organizations focused on constructive engagement in the area of Alzheimer's disease and other neurological disease.
See Russell Katz' presentation (PDF)
See Dr. Celia Witten's presentation (PDF)

September 27, 2007
ACT-AD hosts a member summit in Washington, DC to recap progress the coalition has made in 2007 and showcase planned activities for 2008.
See speaker presentation (PDF)

July 25, 2007
Avalere Health holds an audio conference to discuss the ACT-AD-sponsored study on the way the FDA reviews potential Alzheimer's disease, HIV/AIDS, and cancer therapies.
See speaker presentation (PDF)

June 5, 2007
An ACT-AD-sponsored study by Avalere Health reveals differences in the way the FDA reviews potential Alzheimer's disease, HIV/AIDS, and cancer therapies.
See Press Release (PDF)

April 25, 2007
ACT-AD submits letters to House and Senate subcommittees that handle FDA appropriations outlining FDA’s need for more resources to review promising AD therapies.

May 14, 2007
ACT-AD press briefing to release study of first economic projection of social value of treatments that delay onset of Alzheimer’s Disease.
See Press Release (PDF)
Read Report (PDF)
Speaker Bios (PDF)

April 27, 2006
First major study of Baby Boomer Attitudes on Alzheimer's released by ACT-AD.
Read survey results (PDF)
See press release (PDF)